6 results about "Cyclophilin" patented technology

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

The present invention concerns the use of peptidyl-prolyl isomerase cyclophilin 40 (CyP40) for reduction of neurotoxic fibrils and treatment and prevention of neurodegenerative diseases associated with amyloid fibril aggregation. Aspects of the invention include compositions, methods, dosage forms, and kits for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation in a human or animal subject, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using CyP40, or a biologically active fragment thereof.

The invention provides antibodies, antibody-drug conjugates, bispecific T cell engagers (BiTEs), and chimeric antigen receptors (CARs) that target transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Such antibodies, antibody-drug conjugates, BiTEs, and CARs can be used, e.g., in methods for treating a cancer (e.g., multiple myeloma), an autoimmune disorder (e.g., characterized by a high titer of antibodies contributing to the disorder), or a plasma cell disease disorder (e.g., plasma cell dyscrasias) in a subject in need thereof.

The present invention provides compounds for use in selectively modulating cyclophilin mediated processes in general. In particular, the invention provides compounds for use in treating diseases such as hyper-proliferative disorders, immunity and inflammation disorders and metabolic dysfunction associated steatohepatitis. Additionally or alternatively, the present invention particularly provides compounds for use in engaging an organism's immune system to target a specific cell, specific cells, a cell-type, an organelle or an organ in that organism.

The present invention relates to stilbene derivatives and a method for preparing the same. More particularly, the present invention relates to novel stilbene derivatives which inhibit the function of cyclophilins and are effective in preventing cyclophilin-related diseases or treating symptoms thereof, and a method for preparing the same.

This invention discloses a Cyclophilin antibacterial protein gene from the Minjiang lily. LrCYP1 Its nucleotide sequence is as described in SEQ ID NO: 1, encoding a protein with the amino acid sequence shown in SEQ ID NO: 2. This invention confirms through functional genomics-related research. LrCYP1 The gene has the function of enhancing plant antifungal resistance, and the antifungal properties of this invention... LrCYP1 Genes were constructed into plant expression vectors and overexpressed in tobacco. The transgenic tobacco plants exhibited strong resistance to fungal infection, demonstrating the effectiveness of overexpression. LrCYP1 The genetically modified tobacco plants exhibit high levels of resistance to Alternaria alternata and Pseudomonas spp.